Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 74.66 -1.81 (-2.37%)
price chart
Bristol-Myers Squibb - Abilify
Then it created a SWAT team to exclusively call on nursing homes, where dementia-related psychosis is more prevalent than schizophrenia or bipolar disorder.
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol-Myers in Deal for Amylin Valued at $7 Billion  New York Times (blog)
Bristol's Amylin Deal Heralds Acquisition Hunger  Bloomberg
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Terminally ill patients should have access to last-chance therapies
But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and development of its medicines.
How to Profit From Bristol-Myers Squibb's New Cancer Drugs
Bristol-Myers Squibb announced this week that not one but two of its experimental immunotherapy drugs, not chemotherapy drugs, immunotherapy, have shown amazing results in advanced stages of several types of cancer, and the results are long lasting.
Pfizer, Bristol-Myers's Eliquis Fails to Win FDA Approval
Pfizer Inc. and Bristol-Myers Squibb Co. failed to gain approval of their top experimental drug, the blood thinner Eliquis, from U.S.
FDA rejects blockbuster Eliquis bid, asks Pfizer, BMS for trial clarification  FierceBiotech
Eliquis held up again by FDA, launch delayed at least six months  Medical Marketing and Media
Loneliness Linked To Premature Death
In Monday's online issue of the Archives of Internal Medicine, Dr. Jacob Udell of Brigham and Women's Hospital and Harvard Medical School in Boston and his co-authors said living alone was associated with four-year mortality (14.1 per cent vs. 11.1 per ...
Bristol Immune Drug Success in Cancer May Spur Industry Race
The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
FDA Once Again Delays Approval Of Apixaban (Eliquis)
PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S.
Celegene, Bristol Drugs No Better Than Cheaper Treatments
Celgene Corp.'s Abraxane and Bristol-Myers Squibb Co.'s Ixempra breast-cancer drugs worked no better at delaying tumor growth than a less-expensive chemotherapy that's been the backbone of treatment for 20 years.
Paclitaxel tops newer drugs in comparative breast cancer study  PMLiVE